Home 
Bratislava Medical Journal Ahead of print Bratislava Medical Journal Vol.124, No.5, p.380–386, 2023
Bratislava Medical Journal Ahead of print Bratislava Medical Journal Vol.124, No.5, p.380–386, 2023
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.124, No.5, p.380–386, 2023 |
||
| Title: Antihypertensive effect of telmisartan versus perindopril in hypertensive patients | ||
| Author: Di ZHAO, Hui LIU, Shifang CHEN, Pingshuan DONG | ||
| Abstract: OBJECTIVE: We performed this meta-analysis determining the antihypertensive effect of telmisartan versus perindopril in patients with essential hypertension. BACKGROUND: The comparison of antihypertensive effects between telmisartan and perindopril were controversial. METHODS: Pubmed, Web of Science, and Cochrane Central were searched for all published studies. RESULTS: The antihypertensive effects were assessed in 753 patients included in 7 trials with a mean follow-up of 20 ± 16 weeks. There was no significant difference between telmisartan and perindopril in reduction of systolic blood pressure (SBP, weighted mean differences (WMD) 0.02 (95% confidence interval (CI), ‒2.78, 2.81) mm Hg, p > 0.05). The reduction of diastolic BP (DBP) treated with telmisartan was greater than perindopril in these patients (WMD ‒2.05 (95% CI, ‒2.60, ‒1.49) mm Hg, p < 0.001). Considering the effects of different doses on BP reduction, a sub-analysis was performed. The reduction of DBP treated with 40 mg/day telmisartan was greater than 4‒5 mg/day perindopril (WMD ‒2.18 (95% CI, ‒2.83, ‒1.53) mm Hg, p 0.05). CONCLUSION: The reduction of DBP is greater treated with telmisartan than perindopril in patients with essential hypertension (Tab. 2, Fig. 4, Ref. 34). Text in PDF www.elis.sk |
||
| Keywords: essential hypertension, blood pressure, telmisartan, perindopril, meta-analysis | ||
| Published online: 27-Feb-2023 | ||
| Year: 2023, Volume: 124, Issue: 5 | Page From: 380, Page To: 386 | |
| doi:10.4149/BLL_2023_058 |
||
|
|
 download file |
|